Deadline: 'Deeming'

Opinions pour in as comment period ends on proposed FDA tobacco regs

WASHINGTON -- "The FDA's proposed regulation would decimate the small businesses that make up America's independent e-cigarette industry and remove a powerful tool smokers are using to kick the habit," Gregory Conley, president of the American Vaping Association (AVA), said in comments the group submitted to the U.S. Food & Drug Administration (FDA) on whether certain tobacco products should fall under the agency's authority.

Aug. 8 was the deadline for interested parties to submit public comments to the FDA on the proposed tobacco "deeming" regulations--"Deeming Tobacco Products to Be Subject to the Food, Drug & Cosmetic Act, as Amended by the Family Smoking Prevention & Tobacco Control Act; Regulations on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products" ( FDA-2014-N-0189).

The AVA's comments were among the 75,735 public comments that retailers, wholesalers, manufacturers, associations, tobacco consumers, health organizations, anti-tobacco advocates and others submitted, as well as those of attorneys general, health organizations, anti-tobacco groups and others, on all sides of the issue.

Here is a selection of some of the comments from groups that issued press statements:

"Congress never intended for the regulations it crafted for cigarettes and smokeless tobacco to apply to innovative tobacco-free products," added Conley. "The FDA has the authority to propose alternate regulation for e-cigarettes that wouldn't ban 99% of the products. They should do so for the betterment of public health."

Click here for more details.

Craig Williamson, president of the Cigar Association of America (CAA), said, "Our message to the FDA is that when it comes to regulating the cigar industry, fairness means flexibility. We believe a one-size-fits-all approach to regulation will endanger jobs, consumer rights and America's proud cigar tradition."

Click here to view a summary of CAA responses to a variety of issues raised in proposed FDA regulations.

Continued on next page.

Pages